Tourmaline Ex-Pfizer Drug goes to Trial after Talaris Reverse Merger

Talaris Therapeutics, a biotechnology company, has discontinued its transplant initiatives and is now a part of a reverse merger, providing Tourmaline Bio with the right infrastructure to advance an ex-Pfizer candidate through the next clinical trials.

For six years up to 2016, Pfizer conducted initial clinical studies with the same antibody used to treat Crohn’s disease, lupus, and rheumatoid arthritis. However, their objectives mirrored that of rival companies like Roche and Sanofi-Regeneron, which market Kevzara and Actemra for conditions such as rheumatoid arthritis.

Tourmaline is taking a different approach and has identified a chance to use the same product for “diseases characterized by inflammation and autoantibodies, where IL-6 pathway inhibitors have been underexplored despite compelling signals of clinical benefit.”

The programme will be supported by a $75 million cash placement from their reverse merger.

They anticipate making $210 million from the transaction. And in addition to shareholders receiving a payout of almost $65 million, they will also have over one-fifth ownership of the firm.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.